Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.
Vaccinia melanoma oncolysate is an investigative agent for active specific adjuvant immunotherapy. Viral oncolysate work in animals has led to application of this treatment in humans. Success of initial trials in treatment of melanoma has led to a phase III randomized, prospective, double-blind, multi-institutional trial, which is currently under way.
Scoggin
S D
SD
Department of Surgery, Mount Sinai Medical Center, Miami Beach, FL.
Sivanandham
M
M
Sperry
R G
RG
Wallack
M K
MK
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000951:Antigens, Neoplasm / Q000627:therapeutic use*; D000956:Antigens, Viral / Q000627:therapeutic use*; D002462:Cell Membrane / Q000276:immunology; D004353:Drug Evaluation, Preclinical; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods / Q000592:standards*; D008545:Melanoma / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D012878:Skin Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D014616:Vaccinia virus / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D000956:Antigens, Viral